ArticleBMC cardiovascular disorders2026
Expression and clinical significance of the HIF-1α/VEGF signalling pathway in elderly patients with acute myocardial infarction.
Article in BMC cardiovascular disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the expression level of hypoxia-inducible factor-1α (HIF-1α)/vascular endothelial growth factor (VEGF) signaling pathway in elderly patients with acute myocardial infarction (AMI), and to analyze its relationship with the prognosis of AMI.
methodsA total of 160 elderly patients with AMI were selected from October 2023 to September 2024 in Nanjing Medical University Affiliated Wuxi People's Hospital as the study group, 160 individuals who underwent physical examination during the same period were selected as the control group according to the 1:1 matching principle. The levels of serum HIF-1α and VEGF were compared between the two groups. The study group was treated with percutaneous coronary intervention (PCI). According to the prognosis of patients at 12 months after operation, they were divided into good subgroup and poor subgroup. The clinical data, serum HIF-1α and VEGF levels of the two subgroups were compared. The effect of serum HIF-1α and VEGF on prognosis and its predictive value were analyzed. The accuracy-recall rate (PR) curve was drawn to evaluate the performance of combined prediction. The area under the curve (AUC) was calculated, the DeLong test was used to compare AUCs, and the precision-recall (PR) curve was drawn to evaluate the performance of combined prediction.
resultsThe levels of serum HIF-1α and VEGF in the study group were higher than those in the control group (P < 0.05). The time from onset to admission, the proportion of Killip class IV, the proportion of multivessel disease, N-terminal pro-brain natriuretic peptide (NT-proBNP), HIF-1α and VEGF in the poor subgroup were higher than those in the good subgroup, while left ventricular ejection fraction was lower (P < 0.05). Before and after correction of multivessel disease and NT-proBNP, serum HIF-1α and VEGF levels were the influencing factors of prognosis in patients with AMI (P < 0.05). The AUC of serum HIF-1α and VEGF levels alone and combined prediction were 0.717,0.748 and 0.900, respectively, the AUC of combined prediction was significantly higher than that of the two alone (Z = 3.315,2.832, P = 0.001,0.005), and the best sensitivity and specificity were 83.33% and 84.87%. The DCA curve showed that the combined prediction of serum HIF-1α and VEGF levels in the probability range of 5%-70% could obtain significant positive net benefits. The PR curve showed that the PR-AUC value of serum HIF-1α and VEGF levels in evaluating prognosis was 0.767, which had a high recall rate and accuracy rate.
conclusionSerum HIF-1α and VEGF levels are highly expressed in elderly patients with AMI, and are closely related to the prognosis of patients. The combination of the two can be used to predict the prognosis of patients, provide a reference for the assessment and prognosis of elderly patients with AMI, facilitate early identification of high-risk groups, and provide a reference for subsequent personalized program development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.